GSK And Ionis Announce Phase 3 B Well Program Results For Bepirovirsen Supporting Functional Cure And Global Regulatory Filings Planned From Q1 2026

Primary endpoint met in both trials –

– Bepirovirsen demonstrated a statistically significant and clinically meaningful functional cure rate –

– Chronic hepatitis B (CHB) accounts for ~56% of liver cancer cases and affects more than 250 million people worldwide –

– Global regulatory filings planned from Q1 2026 –